Exploration on Property-efficacy Association of Sovereign Drug Gypsum Fibrosum in Baihu Guizhitang by Integrating Transcriptomicswith Gene Regulatory Network Analysis
|更新时间:2022-12-08
|
Exploration on Property-efficacy Association of Sovereign Drug Gypsum Fibrosum in Baihu Guizhitang by Integrating Transcriptomicswith Gene Regulatory Network Analysis
Chinese Journal of Experimental Traditional Medical FormulaeVol. 29, Issue 1, Pages: 52-60(2023)
LI Weijie,MAO Xia,LIU Yudong,et al.Exploration on Property-efficacy Association of Sovereign Drug Gypsum Fibrosum in Baihu Guizhitang by Integrating Transcriptomicswith Gene Regulatory Network Analysis[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(01):52-60.
LI Weijie,MAO Xia,LIU Yudong,et al.Exploration on Property-efficacy Association of Sovereign Drug Gypsum Fibrosum in Baihu Guizhitang by Integrating Transcriptomicswith Gene Regulatory Network Analysis[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(01):52-60. DOI: 10.13422/j.cnki.syfjx.20222245.
Exploration on Property-efficacy Association of Sovereign Drug Gypsum Fibrosum in Baihu Guizhitang by Integrating Transcriptomicswith Gene Regulatory Network Analysis
To systematically explore the roles and contributions of the sovereign drug Gypsum Fibrosum contained in Baihu Guizhitang (BHGZT) against rheumatoid arthritis (RA) with heat syndrome from property-efficacy association by an approach integrating transcriptomics with gene regulatory network analysis.
Method
2
A total of 20 male Lewis rats were randomly assigned into 4 groups: a control group (
n
=5), a group of adjuvant-induced arthritis rat model with heat syndrome (AIA-H,
n
=5), an AIA-H + BHGZT group (BHGZT, 21.4 g·kg
-1
,
n
=5), and an AIA-H + BHGZT without Gypsum Fibrosum group (BHGZT-GYP, 10.7 g·kg
-1
,
n
=5). We combined the gene expression profiling based on AIA-H rat model and "disease-gene-drug effective target" network analysis to predict the major function of Gypsum Fibrosum contained in BHGZT against RA with heat syndrome. Furthermore,
in vivo
experiments with the AIA-H rat model were performed to validate the therapeutic effects on the severity of arthritis based on the representative images of arthritis, limb diameter, infrared thermography, pain thresholds, and joint injury, as well as at the level of immunity-inflammation imbalance. Oil Red O staining was employed for the differentiation of 3T3-L1 pre-adipocytes in the AIA-H rats treated by BHGZT, BHGZT-GYP, and GYP.
Result
2
Gene expression profiling and network analysis demonstrated that Gypsum Fibrosum mainly regulated the energy metabolism disorders and the immunity-inflammation imbalance during the development and progression of RA.
In vivo
experiments showed that both BHGZT and BHGZT-GYP reduced the disease severity of AIA-H rats (
P
<
0.01) by relieving joint redness and distortion, decreasing arthritis score and limb diameter, elevating pain thresholds, alleviating joint erosion, joint inflammation, and bone destruction (
P
<
0.05). Notably, BHGZT outperformed BHGZT-GYP (
P
<
0.05). Both BHGZT and BHGZT-GYP inhibited the pathological changes and decreased the indexes of thymus and spleen (
P
<
0.05), and down-regulated the expression of inflammatory cytokines including Toll-like receptor 4 (TLR4), tumor necrosis factor-alpha (TNF-
α
), interleukin-6 (IL-6), IL-12, IL-1
β
, and IL-18 (
P
<
0.05). In addition, BHGZT and GYP significantly inhibited the adipogenic differentiation of 3T3-L1 cells, with the performance superior to that of BHGZT-GYP.
Conclusion
2
The sovereign drug Gypsum Fibrosum contained in BHGZT played a crucial role in reversing energy metabolism disorders and immunity-inflammation imbalance, which may be associated with its cold property and function of clearing heat and purging fire.
GUO Q , WANG Y , XU D , et al . Rheumatoid arthritis:Pathological mechanisms and modern pharmacologic therapies [J]. Bone Res , 2018 , 6 : 15 - 29 .
ALETAHA D , BINGHAM C , TANAKA Y , et al . Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T):A randomised,double-blind,placebo-controlled,parallel-group,multinational,phase 3 study [J]. Lancet , 2017 , 389 ( 10075 ): 1206 - 1217 .
LÜ S , WANG Q , LI G , et al . The treatment of rheumatoid arthritis using Chinese medicinal plants:From pharmacology to potential molecular mechanisms [J]. J Ethnopharmacol , 2015 , 176 : 177 - 206 .
LI W , MAO X , WANG X , et al . Disease-modifying anti-rheumatic drug prescription Baihu Guizhitang attenuates rheumatoid arthritis via suppressing toll-like receptor 4-mediated NLRP3 inflammasome activation [J]. Front Pharmacol , 2021 , 12 : 743086 - 743100 .
LI W , MAO X , WU H , et al . Deciphering the chemical profile and pharmacological mechanisms of Baihu Guizhitang using ultra-fast liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry coupled with network pharmacology-based investigation [J]. Phytomedicine , 2020 , 67 : 153156 - 153173 .
XU H , ZHANG Y , LIU Z , et al . ETCM:An encyclopaedia of traditional Chinese medicine [J]. Nucleic Acids Res , 2019 , 47 ( D1 ): D976 - D982 .
SZKLARCZYK D , FRANCESCHINI A , WYDER S , et al . STRING v10:Protein-protein interaction networks,integrated over the tree of life [J]. Nucleic Acids Res , 2015 , 43 ( Database issue ): D447 - D452 .
WANG Y , LIU Z , LI C , et al . Drug target prediction based on the herbs components:The study on the multitargets pharmacological mechanism of Qishenkeli acting on the coronary heart disease [J]. Evid Based Complement Alternat Med , 2012 , doi: 10.1155/2012/698531 http://dx.doi.org/10.1155/2012/698531 .
KANEHISA M , SATO Y , KAWASHIMA M . KEGG mapping tools for uncovering hidden features in biological data [J]. Protein Sci , 2022 , 31 ( 1 ): 47 - 53 .
MAO X , LI W , CHEN W , et al . Exploring and characterizing a novel combination of paeoniflorin and talatizidine for the treatment of rheumatoid arthritis [J]. Pharmacol Res , 2020 , 153 : 104658 - 104673 .
MOSSIAT C , LAROCHE D , PRATI C , et al . Association between arthritis score at the onset of the disease and long-term locomotor outcome in adjuvant-induced arthritis in rats [J]. Arthritis Res Ther , 2015 , 17 ( 1 ): 184 - 196 .